Clinical Trials · NCT06192108
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 962
- Start date
- Jan 2024
- Locations
- 74 sites, 6 countries
- Primary endpoint
- Change From Baseline in HbA1c [Noninferiority Analysis]